United States: According to the recent report shared by Bavarian Nordic, a Danish biotech company rose by 13 percent on Thursday following its stronger-than-expected earnings and announced a mega vaccine order from an unnamed European country in between the prevalent mpox outbreak.
More about the news
As per Reuters, Bavarian Nordic announced the revenue for the second quarter, which is 1.43 billion Danish Krone, or USD 213 million, where the operating cost stands at 420 million kroner, ahead of analyst expectations, as CNBC reported.
The shares were reported to have shot up by 13 percent by 11:58 a.m. London time.
More about the bulk order
The report suggested that on Wednesday, the company received a whopping 440,000 dose order of mpox and smallpox vaccines to be delivered to an unnamed European country.
Moreover, the company said that the order is seen as a part of Bavarian Nordic’s original 2024 guidance and would not have an impact on the remaining capacity this year, as reported by CNBC.
The WHO declaration of global emergency
The demand for vaccines has risen following the declaration by WHO to consider mpox a global public health emergency after the widespread cases occurring in the Democratic Republic of Congo (DRC) to neighboring countries.
As per the CEO Paul Chaplin, the order demands showcase an increasing acknowledgment by countries of the need of the hour to be prepared for the virus.
He said, “Since the last mpox outbreak in 2022/23, Bavarian Nordic has established a strong strategic partnership with a number of authorities that have recognized the need to improve their preparedness against smallpox and mpox,” as CNBC reported.
He also mentioned that the firm possesses the capacity to cater to almost ten million doses of vaccine demand this year, where two million of which would further be made available.